Destiny Pharma (LON:DEST) Stock Price Down 30.1% – Should You Sell?

Destiny Pharma plc (LON:DEST) traded down 30.1% during mid-day trading on Friday . The company traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). 4,179,453 shares were traded during trading, an increase of 484% from the average session volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.05).

Destiny Pharma Price Performance

The firm has a market cap of £2.87 million, a PE ratio of -50.00 and a beta of 0.22. The business’s fifty day moving average is GBX 3 and its 200-day moving average is GBX 6.24.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.